Monalizumab
Monalizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against NKG2-A/NKG2-B type II integral membrane protein.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | 4 | 1 | — | — | 5 | ||
| Squamous cell carcinoma of head and neck | D000077195 | 1 | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 1 | 2 | — | — | — | 2 | |
| Squamous cell carcinoma | D002294 | 1 | 2 | — | — | — | 2 | ||
| Head and neck neoplasms | D006258 | 1 | 1 | — | — | — | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | 1 | — | — | — | 1 | |
| Esophageal neoplasms | D004938 | C15 | 1 | 1 | — | — | — | 1 | |
| Adenocarcinoma | D000230 | 1 | 1 | — | — | — | 1 | ||
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MONALIZUMAB |
| INN | monalizumab |
| Description | Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies; narcotic agonists/antagonists (normorphine type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1228763-95-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297787 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12824 |
| UNII ID | 3ZXZ2V0588 (ChemIDplus, GSRS) |
Target
Agency Approved
KLRC1
KLRC1
Organism
Homo sapiens
Gene name
KLRC1
Gene synonyms
NKG2A
NCBI Gene ID
Protein name
NKG2-A/NKG2-B type II integral membrane protein
Protein synonyms
C-lectin type II protein, CD159 antigen-like family member A, CD159a, killer cell lectin-like receptor subfamily C, member 1, natural killer cell lectin, natural killer group protein 2, NK cell receptor A, NKG2-1/B activating NK receptor, NKG2-A/B type II integral membrane protein, NKG2-A/B-activating NK receptor
Uniprot ID
Mouse ortholog
—
—
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 536 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more